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T
he prevalence of diabetes for all age-
groups worldwide was estimated to
be 2.8% (171 million) in the year
2000, and the projected number could
rise to 4.4% (366 million) in 2030 (1).
This rapid rise is mainly attributable to
the increase of diabetes. The continuing
escalation of obesity and the metabolic
syndrome contribute to the upsurge in
frequency of diabetes (2,3).
Interestingly, the appreciation in the
number of people 65 years of age was
found to be the most important demo-
graphic change to diabetes prevalence
around the world, indicating that the “di-
abetesepidemic”willcontinueeveniflev-
els of obesity remain constant. Therefore,
it is likely that future diabetes preponder-
ance is underestimated, given the grow-
ing frequency of obesity (1). Because the
vast majority of diabetic patients have
type 2 diabetes and almost all the studies
were performed in such subjects, in this
article, “type 2 diabetes” will be referred
to as “diabetes.”
DIABETES AS A MAJOR
RISK FACTOR FOR
CARDIOVASCULAR
DISEASE— Cardiovascular disease
(CVD) is one of the foremost causes of
mortality and is a major contributor to
morbidity for individuals with diabetes.
In addition, diabetes is an independent
risk factor for macrovascular disease, as
are the common coexisting conditions
(hypertension and dyslipidemia). The
U.K. Prospective Diabetes Study (UKPDS)
evaluated baseline risk factors for coro-
nary artery disease in patients with newly
diagnosed diabetes without evidence of
vascular disease. When comparing the
relative contribution of the three modiﬁ-
able coexisting conditions (dyslipidemia,
hypertension, and hyperglycemia) with
developmentoffuturecoronaryheartdis-
ease (CHD), the estimated hazard ratio
(HR) for the upper third, relative to the
lower third, for LDL cholesterol, systolic
bloodpressure,andA1Cwere2.26,1.82,
and 1.52, respectively (4). This ﬁnding
supports the notion that dyslipidemia,
and speciﬁcally LDL cholesterol, are ma-
jorcontributorstotheincreasedCHDrisk
in patients with diabetes (4,5). Hypergly-
cemia occurs at a far later stage in the se-
quence of events from insulin resistance
tofrankdiabetes,whereaslipoproteinab-
normalities are manifested during the
pre-diabetic stage and contribute sub-
stantially to the increased risk of macro-
vascular disease. The most common
pattern of dyslipidemia in diabetic pa-
tients is elevated triglyceride levels and
decreased HDL cholesterol levels. Al-
though the mean concentration of LDL
cholesterolinpatientswithdiabetesisnot
signiﬁcantly different from that in indi-
viduals without diabetes, qualitative
changes in LDL cholesterol may be
present. Patients with diabetes tend to
have a higher proportion of LDL particles
that are smaller and denser, are more sus-
ceptibletooxidation,andmaytherebyin-
crease the risk of cardiovascular events
(6,7). The Framingham cohort (8), and
morerecentdata,haveestablishedtheno-
tionthatdiabetesisassociatedwithatwo-
to fourfold increased risk of both CHD
and stroke (9–11). Furthermore, diabetic
patients who develop cardiovascular
complications do not fare as well as non-
diabetic patients, namely the case-fatality
rates for myocardial infarction (MI) and
stroke are also higher among diabetic pa-
tients, emphasizing the important need
for primary prevention of cardiovascular
complications in these individuals. The
realization that diabetes is considered a
major risk for cardiovascular events
evolved to the concept regarding diabetes
as a “CHD-risk equivalent.” This concept
wasﬁrstintroducedinthe2001American
National Cholesterol Education Program
AdultTreatmentPanelIII(NCEPATPIII)
guidelines(12),basedonstudiesshowing
that the absolute risk for ﬁrst major coro-
nary events for diabetic individuals ap-
proximates that for recurrent events in
nondiabetic individuals with clinical
CHD (12,13). This hypothesis was reiter-
ated in the 2004 NCEP report, and cur-
rent treatment recommendations
consider patients with diabetes to be
CHD-risk equivalents and have estab-
lishedmoreaggressivetreatmentgoalsfor
LDLcholesterol,aswellasforbloodpres-
sure lowering (14–17). However, other
studies suggested that although diabetic
patients are at increased risk for CHD
morbidity and mortality, the risk may not
be as high as previously perceived, and
also question whether diabetic patients
without vascular disease should be cate-
gorized as being at similar risk.
DIABETES IS A CHD-RISK
EQUIVALENT— The seminal article
by Haffner et al. (13) is the basis for this
premise.ThisobservationalFinnishstudy
examined the 7-year incidence of cardio-
vascular events among 890 patients with
diabetes who had no history of MI, com-
pared with 69 patients with previous MI.
The risk of death from CHD was not sig-
niﬁcantly different between the two
groups, with an adjusted HR of 1.2. The
main ﬂaw of this study was the lack of
power to detect differences between the
two groups because of the small sample
size, leading to wide CIs around the risk
ratios. In an effort to correct this weak-
ness, follow-up of this cohort was pro-
longed for up to 18 years (18). Diabetic
patients without prior MI had an HR of
0.9 for the risk of CHD mortality com-
pared with nondiabetic patients with
priorMIinfarction.Furthermore,withre-
spect to other deﬁnitions of CHD, the
prognosis for patients with diabetes with-
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that for nondiabetic patients with prior
CHD, particularly for women. Similar re-
sults were found in the Renfrew and Pais-
ley Survey, a prospective cohort study of
7,052 men and 8,354 women, who were
followed up for 25 years (19). Diabetes
withoutpreviousCHDwasfoundtocarry
a lifetime fatality risk from vascular dis-
ease equal to that of CHD alone. Women
were found to be at particular risk. The
adjusted HR for CHD mortality in men
with diabetes only, compared with men
who had CHD, was 1.17. The corre-
sponding HR for women was 1.97. In the
Nurse’s Health Study, in a cohort of
121,700womenfollowedupfor20years,
theage-adjustedrelativeriskoffatalCHD
wasalmostsimilarbetweenwomenwitha
historyofdiabetesandnoCHDandthose
with a history of CHD and no diabetes at
baseline(8.7and10.6,respectively)(20).
In the Women’s Pooling Project, a pro-
spective study that combined data from
nine long-term epidemiological studies,
27,269 women were followed up for an
averageof8.3years(10).Diabeticwomen
without CVD were found to have a fatal
stroke risk similar to that of nondiabetic
females who had a history of prior stroke
andasimilarriskfactorproﬁle(HR1.29).
DIABETES IS NOT A CHD-
RISK EQUIVALENT— In cross-
sectional and cohort studies from Scot-
land,patientswithdiabeteswerefoundto
be at lower risk of cardiovascular out-
comes compared with patients with es-
tablished CHD (21). In the cross-
sectional study (n  1,155), the adjusted
risk ratio for death from all-cause mortal-
ity was 2.27 for patients with a previous
MI compared with diabetic patients with-
out CHD. In the cohort study (n 
3,477), the diabetic group was at a lower
risk for all-cause and cardiovascular mor-
tality, compared with those who had dia-
betes but no CHD. However, the reduced
risk of diabetic patients without CHD
seemed to occur mainly in the early pe-
riod of follow-up, with the gradients of
thecurvesconvergingafter3years(21).
In the Atherosclerosis Risk in Communi-
ties (ARIC) study, a population-based co-
hort from four U.S. communities (n 
13,790) with over 11 years of follow-up,
diabeticpatientswithoutMIhadlessdan-
ger of CHD events and mortality from
CVD, compared with nondiabetic pa-
tients with a prior MI. However, the pos-
sibility for stroke was similar in these
groups. After adjustment for multiple
baseline risk factors, patients with a his-
tory of MI without diabetes at baseline
had a 1.9 times greater likelihood of fatal
CHD or nonfatal MI, compared with dia-
betic patients without a prior MI. The
nondiabetic patients with MI also had a
1.8 times higher risk of CVD mortality
than diabetic patients without MI. In the
Prospective Cardiovascular Munster
(PROCAM) study (n  5,389), only
26.5% of men with diabetes were esti-
mated as having a 10-year coronary event
risk at or above the threshold of 20%,
which is regarded as being equivalent to
thatofestablishedCHD.Thepositivepre-
dictive value of a high-risk estimate was
only 35% in diabetic men. In the Physi-
cian’s Health Study, a prospective cohort
analysis of 91,285 U.S. male physicians,
CHD was a stronger predictor of death
from CHD than diabetes (22). The risk of
CHD mortality was 3.3% among men
withdiabetesandwithoutCHDand5.6%
among men with CHD and without dia-
betes. For all-cause mortality, the magni-
tude of excess vulnerability presented by
diabetes was similar to that of a history of
CHD. Similar results were found in the
Multiple Risk Factor Intervention Trial
(MRFIT) (9). The adjusted HR for all-
cause mortality for individuals with MI
only, compared with diabetes only, was
0.97, but the pattern of demise was dif-
ferent: higher coronary mortality and
lower mortality from noncardiovascular
causes in individuals with MI only, com-
paredwithindividualswithdiabetesonly.
CALCULATING THE RISK OF
DIABETIC PATIENTS— Different
risk calculators vary in their attitude to-
ward diabetes as a CHD risk factor. The
Framingham risk calculator uses age, sex,
blood pressure, cholesterol (total and
HDL), and smoking for calculating the
risk,withdiabetesconsideredaCHD-risk
equivalent, requiring no further risk cal-
culation (12). The European Systematic
Coronary Risk Evaluation (SCORE) cal-
culator uses a similar approach. Patients
with diabetes are automatically assigned
to the highest risk category, and further
hazard calculation is unnecessary (23).
Other risk calculators treat diabetes the
same as other danger factors and include
this condition in the probability equa-
tions.Anexampleforsuchanapproachis
the PROCAM risk calculator. Other risk
calculators were speciﬁcally designed for
patients with diabetes; the UKPDS risk
engine uses glycemia, systolic blood pres-
sure, lipid levels, age, sex, ethnic group,
smoking status, and time since diagnosis
ofdiabetestoformadiabetes-speciﬁcrisk
assessment (24). Other calculators com-
bine a general and a diabetes-speciﬁc ap-
proach. Recently, a modiﬁcation of the
Framingham calculator was proposed for
women, which included A1C in the risk
calculation if the patient was diabetic.
CHOLESTEROL REDUCTION
AND CARDIOVASCULAR
RISK REDUCTION IN
DIABETIC PATIENTS— The vast
majority of clinical trials examining cho-
lesterol reduction as a means to reduce
cardiovascular risk were performed using
HMG-CoA reductase inhibitors (statins).
Only three trials recruited diabetic pa-
tients exclusively, but some other trials
included sufﬁcient diabetic patients to fa-
cilitate prespeciﬁed or post hoc analyses
of the effect of statins in these patients.
SECONDARY PREVENTION
AND MIXED SECONDARY
AND PRIMARY
PREVENTION TRIAL— In a post
hoc analysis of the Scandinavian Simva-
statinSurvivalStudy(4S),asigniﬁcantre-
duction in major coronary events and
revascularizationwasobservedinsimvas-
tatin-treated diabetic patients (25) (Table
1).Totalandcoronarymortalitywerealso
reduced, but not signiﬁcantly, because of
the small sample size. Notably, risk re-
duction for major coronary events was
greater in diabetic (42%) than in nondia-
betic patients (32%). In the Cholesterol
and Recurrent Events (CARE) trial, prav-
astatin treatment, compared with pla-
cebo, reduced by 25% the relative risk of
coronary events for both diabetic and
nondiabetic patients (26). In the Long-
Term Intervention with Pravastatin in
Ischemic Disease (LIPID) trial, treatment
with pravastatin was associated with a re-
duction of 19% in major CHD (albeit not
statistically signiﬁcant) (27). A possible
explanation for the nonsigniﬁcant reduc-
tion may be the lower baseline risk: dia-
betic patients treated with placebo in the
LIPID trial had a 15.9% chance of fatal
CHD and nonfatal MI compared with a
likelihood of 20% in CARE and 35%
in 4S. The Heart Protection Study (HPS),
the largest statin trial, comprised almost
6,000 diabetic patients (28). For the ﬁrst
occurrence of major vascular events
among participants with diabetes, there
was a statistically signiﬁcant 22% reduc-
tionintheeventrate,whichwassimilarto
that among the other high-risk individu-
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Prevention of Coronary Heart Disease
End Points (ASPEN) trial examined the
effect of 10 mg atorvastatin versus pla-
cebo on major cardiovascular events in
2,410 subjects with diabetes (29). This
trial was originally designed as a secondary
prevention trial for individuals with CHD.
However,theprotocolwasamendedwithin
2 years of initiation of the study to enable
enrollment of subjects without prior
CHD. Subsequent treatment guidelines
necessitated all secondary prevention
subjects,andprimarypreventionsubjects
who developed a primary CVD end point
during the trial, to discontinue the study
medication and commence active ther-
apy. In this trial, there was no difference
in major cardiovascular events between
the atorvastatin and placebo groups. In
the Diabetes and Dialysis Study, 1,255
patients with diabetes receiving hemodi-
alysis (30% of whom had CHD), were
randomly assigned to receive 20 mg ator-
vastatin per day or placebo (30). Atorva-
statin had no signiﬁcant effect on the
composite primary end point of cardio-
vascular death, nonfatal MI, and stroke.
These results were observed despite a
high incidence rate of major cardiovascu-
lar events, which was the highest in all
long-term prospective statin therapy tri-
als. It is noteworthy that the subgroup
analyses showed no difference in out-
comes for baseline LDL cholesterol level,
orpresenceorabsenceofCVD.Apossible
explanation for the lack of beneﬁt from
statin therapy in this trial may be due to
thetypeofpatientsstudied.Inpatientson
dialysis, other pathogenetic factors may
bemoreprominentincontributingtocar-
diovascular risk. It is of interest that, in
patients with end-stage renal disease,
there is a kind of “reverse epidemiology,”
with inverse associations between blood
cholesterol (as well as other risk factors
including hypertension and obesity) and
all-causeorcardiovascularmortality(31).
PRIMARY PREVENTION
TRIALS— The West of Scotland Cor-
onary Prevention Study and the Air
Force/Texas Coronary Atherosclerosis
Prevention Study (AFCAPS/TexCAPS)
comprised only a small number of dia-
betic patients (1 and 2% of the patients
studied, respectively), precluding a
meaningful subanalysis of this patient
population.
In the Anglo-Scandinavian Cardiac
Outcomes Trial–Lipid-Lowering Arm
(ASCOT-LLA), 24% of the 19,342 hyper-
tensive patients enrolled had diabetes
(32). The proportional effect of atorvasta-
tin on the primary end point of nonfatal
MI and fatal CHD did not differ signiﬁ-
cantly in any prespeciﬁed subgroup from
that noted overall, although the beneﬁt
was not signiﬁcant in patients with diabe-
tes. However, the absolute number of
events among patients with diabetes was
small, so the study may have had inade-
quate power, especially due to the short-
ened follow-up period (the study was
stoppedprematurelyafteramedianof3.3
years’ follow-up because of the obvious
beneﬁtofatorvastatin).Anotherissuewas
the high rate of statin use among patients
with diabetes assigned to placebo: 14%
comparedwith8%inindividualswithout
diabetes. The Collaborative Atorvastatin
Diabetes Study (CARDS) is the only dia-
betes-speciﬁc primary prevention trial
performed (33). In this trial, 2,838 dia-
betic patients without CHD, but with at
least one other risk factor (hypertension,
retinopathy, albuminuria, or smoking),
were randomized to 10 mg atorvastatin
daily, or placebo. The primary end point
was the time to ﬁrst occurrence of acute
CHD events, coronary revascularization,
orstroke.Thetrialwasterminated2years
earlier than expected because the pre-
speciﬁed stopping rule for efﬁcacy had
been met. There was a signiﬁcant relative
risk reduction of 37%, with 37 major vas-
Table 1—Cholesterol reduction and cardiovascular risk reduction in diabetic patients
Study (reference)
Number of
patients with
diabetes Drug and dose
Mean baseline
LDL cholesterol
(mg/dl)
Mean achieved
LDL cholesterol
(mg/dl)
% Reduction in
major adverse
coronary
events* P
Secondary prevention
and mixed trials
4S (25) 483 Simvastatin 20–40 mg 189 117 42 0.001
CARE (26) 586 Pravastatin 40 mg 136 96 25 0.05
LIPID (27) 782 Pravastatin 40 mg 150† 112† 19 NS
HPS (28) 5,936 Simvastatin 40 mg 124 89 22 0.0001
ASPEN (29) 2,410 Atorvastatin 10 mg 113 79 10 NS
Diabetes and Dialysis
(30) 1,255 Atorvastatin 20 mg 123 72 8 NS
Primary prevention trials
ASCOT (31) 2,532 Atorvastatin 10 mg 132† 81† 36 0.0005
CARDS (32) 2,838 Atorvastatin 10 mg 117 81 37 0.001
Intensive versus less
intensive therapy
PROVE-IT (34) 734 Atorvastatin 80 mg vs.
pravastatin 40 mg
106† 62 vs. 95†‡ 17 NS
TNT (35) 1,231 Atorvastatin 80 mg vs.
atorvastatin 10 mg
99 73 vs. 99‡ 29 0.0001
A to Z (36) 1,059 Simvastatin 40/80 mg vs.
simvastatin 0/20 mg
111† 66 vs. 81†‡ 14 NS
*According to study deﬁnition. †Value for the entire study population. ‡Intensive versus moderate therapy.
Treating diabetes with statin drugs
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treated for 4 years. Overall mortality was
also reduced with atorvastatin, although
justfailingtoreachstatisticalsigniﬁcance.
INTENSIVE VERSUS
MODERATE LIPID
LOWERING WITH
STATINS— The PROVE-IT study
compared 80 mg atorvastatin to 40 mg
pravastatin (LDL cholesterol level
achieved,62vs.95mg/dl,respectively)in
patients with acute coronary syndrome
(34); 18% of the patients enrolled had di-
abetes. The beneﬁt of high-dose atorva-
statinontheprimarycompositeendpoint
of death from any all-cause mortality, MI,
unstable angina, revascularization, and
stroke was consistent among the pre-
speciﬁed subgroups, including diabetic
patients. The Treating-to-New-Targets
(TNT)studycompared80mgwith10mg
atorvastatin (LDL cholesterol level
achieved, 72 vs. 99 mg/dl, respectively),
in patients with stable CHD. Of the
10,001 patients enrolled in this study,
5,584hadmetabolicsyndromeand1,231
had diabetes (35). High-dose (compared
with low-dose) atorvastatin reduced the
riskoftheprimaryendpoint(timetoﬁrst
major cardiovascular event) in diabetic
patients, with a relative risk reduction
similar to that observed in nondiabetic
patients. In the A to Z Trial, which com-
pared early intensive versus a delayed
conservative simvastatin treatment in pa-
tients with acute coronary syndromes
(LDL cholesterol level achieved 63 vs. 77
mg/dl, respectively), 24% of patients had
diabetes (36). In this study, the intensive
strategy did not signiﬁcantly reduce the
risk for the composite end point of car-
diovascular death, nonfatal MI, readmis-
sion for acute coronary syndrome, and
stroke, and the diabetic subgroup was no
exception.
SHOULD ALL DIABETIC
PATIENTS BE TREATED
WITH A STATIN?— It has been
shownindifferentpopulationsthatapos-
itive log-linear relation exists between
blood LDL cholesterol and the risk of
CHD, and this association persists well
below the range of typical cholesterol lev-
els (37–39).
A large body of data has provided the
evidence that LDL lowering with statins,
inavarietyofpopulationsatriskforCVD,
including patients with diabetes, reduced
the relative risk for cardiovascular events
(39,40). However, it is important to em-
phasize that treatment decisions should
be based not on the reduction in relative
risk, but on the reduction of absolute risk.
Therefore, in patients with a high ab-
solute cardiovascular risk, even a modest
reduction in relative risk provides sub-
stantial clinical beneﬁts. In addition,
other parameters should also be consid-
ered, namely life expectancy, concomi-
tant diseases, and quality of life.
To address the controversy as to
whether diabetic patients without vascu-
lar disease should be treated in a manner
similar to patients with established CHD,
the absolute risk for developing CVD in
diabetic patients should be clariﬁed. Are
risks similar in all diabetic patients? Can
we consider all diabetic patients to be
CHD-risk equivalents? Is intensive treat-
ment in diabetic patients without CHD
morebeneﬁcialthanmoderatetreatment?
CARDIOVASCULAR RISK
ASSESSMENT OF DIABETIC
PATIENTS: IMPLICATIONS
IN PRACTICE GUIDELINES — The
NCEP ATP III guidelines recognized the
fact that not all diabetic patients are alike
(12). The authors chose to consider all
diabetic patients to be in the highest-risk
category, because of the notion that most
seemingly low-risk diabetic patients are
younger and do not manifest multiple
majorriskfactors.However,iftheirriskis
projected to age 65 years, the majority
will attain a risk of 20%. For example, in
the Third National Health and Nutrition
Examination Survey (NHANES III), indi-
viduals aged 50 years, with both diabetes
and metabolic syndrome, had the highest
prevalence of CHD (19.2%), compared
with individuals with neither condition.
Among people with diabetes, the preva-
lence of metabolic syndrome was ex-
tremelyhigh(86%).Inthesmallsubsetof
diabetic patients who did not meet the
criteria for metabolic syndrome, the inci-
dence of CHD was only 7.5%, which was
comparable to that of individuals with
neither diabetes nor metabolic syndrome
(8.7%). Furthermore, diabetic patients
have an increased case-fatality rate with
anMI,andtheiroverallprognosisforsur-
vival is far worse once they develop CHD
than it is for CHD patients without diabe-
tes,makingprimarypreventionofcardio-
vascular events extremely important in
this patient population. Therefore, an
LDL cholesterol goal of 100 mg/dl was
set for all patients with diabetes. It is
stated that if a patient with diabetes and
no CVD is considered to be at lower risk,
because of young age or lack of other risk
factors, an LDL-lowering drug should not
be started if the LDL cholesterol level is
130 mg/dl, depending on clinical
judgment.
Inthe2004NCEPreport(12),updat-
ing the ATP III guidelines, the view of di-
abetesasahigh-riskstatewasunchanged,
andanLDLcholesterolgoalof70mg/dl
was considered optional. The European
guidelinestookasimilarapproach,stat-
ing that “patients...w h ohave diabe-
t e s...havealreadydeclaredthemselves
to be at markedly increased risk” without
a need for further risk stratiﬁcation (23).
An LDL cholesterol goal of 100 mg/dl
was set, with a goal of 80 mg/dl if feasi-
ble. A recent scientiﬁc statement by the
American Heart Association and the
American Diabetes Association took a
more cautious approach (41). In individ-
uals with diabetes who are over the age of
40 years, without overt CVD, but with
one or more major CVD risk factor (hy-
pertension, low HDL cholesterol levels,
smoking, and family history of premature
CHD), the primary goal is an LDL choles-
terol level 100 mg/dl. If LDL-lowering
drugsareused,areductionofatleast30–
40% in LDL cholesterol levels should be
obtained. If baseline LDL cholesterol is
100mg/dl,statintherapyshouldbeini-
tiated on the basis of risk factor assess-
ment and clinical judgment. In
individuals with diabetes who are under
the age of 40 years, without overt CVD,
but who are estimated to be at increased
risk of CVD, either by clinical judgment
or by risk calculator, the LDL cholesterol
goal is 100 mg/dl, and LDL-lowering
drugs should be considered if lifestyle
changes do not achieve the goal. The Ca-
nadian guidelines use a similar approach,
stating that most adults with diabetes
should be considered at high risk for vas-
cular disease. The exceptions are younger
patients with shorter duration of disease
and without diabetic complications (in-
cluding established CVD) and without
other CVD risk factors. A computerized
riskengine(e.g.,UKPDSriskengine,Car-
diovascular Life Expectancy Model) can
be used to estimate vascular risk (24).
LDL cholesterol lowering with statins
has been previously shown to be beneﬁ-
cial with a substantial risk reduction of
major vascular events in a wide spectrum
of high-risk participants, irrespective of
baseline lipid proﬁle or other characteris-
tics, including diabetes. However, a small
number of trials recruited diabetic pa-
tients exclusively, and other trials did not
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tients to facilitate prespeciﬁed or post hoc
analyses of the effect of statins in these
patients. In addition, there was scant in-
formation about the separate effects of st-
atins on cardiovascular complications
and whether the beneﬁts of statin therapy
are worthwhile in people with diabetes
without a history of clinically manifested
vascular disease. A recent meta-analysis
addressed these issues and examined the
efﬁcacyofstatintherapyin18,686people
with diabetes in 14 randomized trials
(39). During a mean follow-up of 4.3
years, statin therapy signiﬁcantly reduced
the risk of all-cause and vascular mortal-
ity, major vascular events, MI, coronary
revascularization, and stroke. A salient
point is that the proportional effect of sta-
tin therapy in diabetic patients was simi-
lar, irrespective of whether there was a
priorhistoryofvasculardiseaseandother
baseline characteristics, namely sex, age,
hypertension, pretreatment LDL choles-
terol levels, other lipid levels, BMI, smok-
ing, and estimated glomerular ﬁltration
rate.Theauthorssuggestedthattheuseof
standard doses of statins that reduced
LDL cholesterol by almost 40% would
prevent approximately one-third of pa-
tients from experiencing a major vascular
event. Moreover, a greater decline in LDL
cholesterol levels is expected to further
decrease cardiovascular risk, since the
beneﬁtswerealmostlinearlyrelatedtothe
absolute reduction in LDL cholesterol,
with no threshold below which there was
no further beneﬁt. Not surprisingly, eval-
uation of the outcome of diabetic patients
in the placebo arm of this meta-analysis
revealed that those with a history of vas-
cular disease had the worst outcome
(31.6% risk for major vascular events
during 4.3 years of follow-up). The risk
for developing a major vascular event was
higher in patients with vascular disease
without diabetes, compared with diabetic
patients without vascular disease (23.5
and 11.8%, respectively), the lowest risk
being in patients without diabetes and no
vascular disease (8.3%). This indicates
thatthenotionthatdiabetesisaCHD-risk
equivalent cannot be applied to all dia-
betic patients. The relative risk reduction
ofmajorvasculareventspermillimoleper
liter reduction in LDL cholesterol in par-
ticipants with and without diabetes, and
with or without a history of vascular dis-
ease, was analogous. Despite the fact that
the absolute risk of patients with diabetes
without vascular disease was lower than
nondiabetic patients with vascular dis-
ease, the average risk over a 10-year pe-
riod in those with diabetes, but without
vascular disease, would exceed the U.K.
National Institute for Health and Clinical
Excellence (NICE) threshold of 20% risk
at which level these guidelines recom-
mend statin therapy (39).
Although it is recognized that not all
patients with diabetes are at risk, which is
equivalenttopatientswhohaddeveloped
cardiovascular complications, it is our
recommendation that all patients with di-
abetesshouldbeprescribedstatintherapy
to achieve a reduction in LDL cholesterol
by at least 30–40%, to a target goal of
100 mg/dl (2.60 mmol/l). This ap-
proach is supported by evidence showing
that all diabetic patients are in the highest
risk category, and the majority of those
considered at lower risk, mostly younger
individuals, will attain a risk of 20% over
a 20-year period. This seemingly aggres-
siveapproachisalsojustiﬁedbecausepri-
mary prevention of cardiovascular
complications in diabetic patients is es-
sential because of the high case-fatality
ratesamongindividualswhodevelopcar-
diovascular complications. Furthermore,
this approach simpliﬁes treatment guide-
lines and potentially will increase treat-
ment rates in this high-risk group. It is
important to emphasize that data ob-
tained from a large number of clinical tri-
als have shown that statin-based therapy
is relatively safe. Moreover, recent data
have shown that some generic statins are
cost-effective, and it is expected that
within the next few years, more statins
will be available in the generic form,
which will reduce cost and increase
cost-effectiveness.
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